RVL Pharmaceuticals PLC
RVLP Healthcare Biotechnology
RVL Pharmaceuticals PLC’s revenue for fiscal 2022 (year ended December 2022) was $49.7 million.
Follow RVLP
RVL Pharmaceuticals PLC (RVLP) EV/Sales
As of 21 December 2023, RVL Pharmaceuticals PLC (RVLP) trades at a EV/Sales of 1.0×. Over the past ten years it has ranged from 1.0× (December 2023) to 13.6× (October 2021) — the current reading is the lowest in ten years. That is below the Biotechnology industry median of 9.2× and below the Healthcare sector median of 3.4×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2022 | 2.3× | (56.27%) |
| FY2021 | 5.3× | 10.40% |
| FY2020 | 4.8× | 114.07% |
| FY2019 | 2.3× | 8.18% |
| FY2018 | 2.1× | (17.28%) |
| FY2017 | 2.5× | 0.00% |
| FY2016 | 2.5× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Jun 2023 | 2.6× | (31.25%) |
| Mar 2023 | 3.7× | 59.60% |
| Dec 2022 | 2.3× | (48.03%) |
| Sep 2022 | 4.5× | 20.56% |
| 19 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| KTTA Pasithea Therapeutics Corp. compare | −66.3× |
| LPCN Lipocine Inc. compare | −5.2× |
| ADAPY Adaptimmune Therapeutics PLC compare | 0.1× |
| RVLP RVL Pharmaceuticals PLC | 1.0× |
| CLVSQ Clovis Oncology, Inc. compare | 3.1× |
| CNSY Cerenome, Inc. compare | 3.3× |
| DARE Dare Bioscience, Inc. compare | 4.7× |
| TVRD Tvardi Therapeutics, Inc. compare | 4.8× |
| BCDA BioCardia, Inc. compare | 30.2× |
| Biotechnology industry median | 9.2× |
| Healthcare sector median | 3.4× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)